Investor Presentaiton

80 Investor presentation Full year 2022 Rare disease sales increased by 1%, driven by commercial execution and key brands EsperoctⓇ and Refixia® DKK billion NovoSevenⓇ and NorditropinⓇ account for ~75% of Rare disease sales Rare disease franchise is sustaining growth DKK billion 25 25 4% 1% 4% 1% 4% 1% 4% 1% 20 20 20 15 10 5 0 2019 2020 2021 2022 NovoSevenⓇ NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER Source: Quarterly company announcement Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ 15 8 7 10 8 13 5 11 12 12 2019 2020 2021 2022 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation